DBVTDBV Technologies S.A.
$9.51-33% 1Y
$9.51
$9.5152 weeks$24.54
Latest close: a new 52-week lowOct 8, 2026what changed →
DBVT in its own filings
DBVT's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
352
Events found in the filings · across 574 filings · the record starts in 2014
- Hard flags
- 2
Hard flags
- Most recent filing
- Sep 30, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 21, 2014
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 28, 2026
- Late periodic reportpast_3y
- 2025-03-31
- Delisting notice / listing-rule failure5 occurrences
- 2024-12-16
- SEC comment-letter activity23 occurrences
- 2025-05-27
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 30, 2026DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years.Other event · press release
- Jul 16, 2026Châtillon, France, July 16, 2026.Earnings release · press release
- Jun 29, 2026Châtillon, France, June 29, 2026.Other event · press release
- Jun 5, 2026On June 3, 2026 the Board of Directors (the “Board”) of DBV Technologies S.A. (the “Company”), upon recommendation of the Compensation Committee (the “Committee”) of the Board, approved the DBV Technologies 2026 Performance Share Unit Plan (the “Plan”), and granted performance share units pursuant to the Plan (“PSUs”) …Director or officer change · Form 8-K
- Jun 3, 2026On June 3, 2026, in connection with the shareholder vote at the Annual General Meeting (as defined below), the shareholders of the Company amended the Company’s bylaws ( statuts ), effective immediately.Charter/bylaw amendment or fiscal-year change · Form 8-K
- May 5, 2026On April 30, 2026 the Board of Directors (the “Board”) of DBV Technologies S.A. (the “Company”), upon recommendation of the Compensation Committee (the “Committee”) of the Board, approved the DBV Technologies 2026 Performance Share Unit Plan (the “Plan”), and granted performance share units pursuant to the Plan …Director or officer change · Form 8-K
- Apr 30, 2026Châtillon, France, April 30, 2026.Earnings release · press release
- Mar 26, 2026DBV Technologies Reports Full Year 2025 Financial Results and Business Update.Earnings release · press release
- Mar 2, 2026DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting.Other event · press release
- Jan 20, 2026DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise.Other event · press release
- Dec 16, 2025DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years.Other event · press release
- Oct 30, 2025On October 30, 2025, Philina Lee was appointed to the Board of Directors (the “Board”) of DBV Technologies S.A. (the “Company”) effective immediately, to fill the vacancy created by the resignation of Daniel Soland.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…